Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
In a Hot Line presentation yesterday, Professor Nicholas Mills (University of Edinburgh, Edinburgh, UK) revealed one-year outcomes data from the High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS) trial.(1)
This was a stepped-wedge cluster randomised controlled trial that evaluated the implementation of the ARCHITECTSTAT high-sensitivity cardiac troponin I (hs-cTnI) assay using the sex-specific 99th centile (34 ng/L for men, 16 ng/mL for women) as a diagnostic threshold in 48,282 consecutive patients with suspected acute coronary syndrome from 10 secondary and tertiary care hospitals across Scotland. The primary endpoint of myocardial infarction (MI) or cardiovascular death at one year was compared in patients reclassified as having myocardial injury by the hs-cTnl assay before and after implementation.
Prof. Mills says, “The trial found that implementation of a high-sensitivity cTnl using the 99th centile as the diagnostic threshold increased the frequency of patients with myocardial injury; but only a third had a diagnosis of MI, and implementation was not associated with lower rates of subsequent MI or cardiovascular death at one year.” He continues, “The findings were surprising. But it was encouraging that there was no evidence of misdiagnosis, inappropriate treatment, excess bleeding or harm. Indeed, the length of stay across the trial population was reduced by almost a third suggesting that use of the high-sensitivity test increased the confidence of clinicians to rule out heart disease, with benefits for health service providers.” When discussing next steps, Prof. Mills concludes, “These results are controversial because they suggest that the Universal Definition of Myocardial Infarction needs to move away from a binary threshold to diagnose and guide treatment for MI. It is now up to the research community to find a superior approach.”
1. Shah ASV, et al. Lancet 2018;august28:doi:10.1016/s0140-6736(18)31923-8.
Click here to read other scientific highlights in the ESC Congress news.
About the European Society of Cardiology
The European Society of Cardiology brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2018
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved